
    
      Eligible female subjects will be randomly assigned to one of the three treatment groups.
      Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily
      during study drug treatment. The study duration is approximately six months, which is
      comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a
      one-month follow-up period.
    
  